Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy

Despite tremendous research efforts at every level, globally, there is still a lack of effective drugs for the treatment of Alzheimer′s disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease are not yet clearly understood. This review analyses the relevance of multipl...

Full description

Bibliographic Details
Main Authors: Agnieszka Zagórska, Anna Jaromin
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/15/3337
id doaj-dee5ec9821104e97a9f19bfbf5122966
record_format Article
spelling doaj-dee5ec9821104e97a9f19bfbf51229662020-11-25T02:35:09ZengMDPI AGMolecules1420-30492020-07-01253337333710.3390/molecules25153337Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease TherapyAgnieszka Zagórska0Anna Jaromin1Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, PolandDepartment of Lipids and Liposomes, Faculty of Biotechnology, University of Wroclaw, Wroclaw, 50-383 Wrocław, PolandDespite tremendous research efforts at every level, globally, there is still a lack of effective drugs for the treatment of Alzheimer′s disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease are not yet clearly understood. This review analyses the relevance of multiple ligands in drug discovery for AD as a versatile toolbox for a polypharmacological approach to AD. Herein, we highlight major targets associated with AD, ranging from acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), glycogen synthase kinase 3 beta (GSK-3β), <i>N</i>-methyl-<span style="font-variant: small-caps;">d</span>-aspartate (NMDA) receptor, monoamine oxidases (MAOs), metal ions in the brain, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H<sub>3</sub> receptor), to phosphodiesterases (PDEs), along with a summary of their respective relationship to the disease network. In addition, a multitarget strategy for AD is presented, based on reported milestones in this area and the recent progress that has been achieved with multitargeted-directed ligands (MTDLs). Finally, the latest publications referencing the enlarged panel of new biological targets for AD related to the microglia are highlighted. However, the question of how to find meaningful combinations of targets for an MTDLs approach remains unanswered.https://www.mdpi.com/1420-3049/25/15/3337multitarget drug discoveryMTDLstacrinedonepezilAChE inhibitorsBACE-1 inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Agnieszka Zagórska
Anna Jaromin
spellingShingle Agnieszka Zagórska
Anna Jaromin
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Molecules
multitarget drug discovery
MTDLs
tacrine
donepezil
AChE inhibitors
BACE-1 inhibitors
author_facet Agnieszka Zagórska
Anna Jaromin
author_sort Agnieszka Zagórska
title Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
title_short Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
title_full Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
title_fullStr Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
title_full_unstemmed Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
title_sort perspectives for new and more efficient multifunctional ligands for alzheimer′s disease therapy
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2020-07-01
description Despite tremendous research efforts at every level, globally, there is still a lack of effective drugs for the treatment of Alzheimer′s disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease are not yet clearly understood. This review analyses the relevance of multiple ligands in drug discovery for AD as a versatile toolbox for a polypharmacological approach to AD. Herein, we highlight major targets associated with AD, ranging from acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), glycogen synthase kinase 3 beta (GSK-3β), <i>N</i>-methyl-<span style="font-variant: small-caps;">d</span>-aspartate (NMDA) receptor, monoamine oxidases (MAOs), metal ions in the brain, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H<sub>3</sub> receptor), to phosphodiesterases (PDEs), along with a summary of their respective relationship to the disease network. In addition, a multitarget strategy for AD is presented, based on reported milestones in this area and the recent progress that has been achieved with multitargeted-directed ligands (MTDLs). Finally, the latest publications referencing the enlarged panel of new biological targets for AD related to the microglia are highlighted. However, the question of how to find meaningful combinations of targets for an MTDLs approach remains unanswered.
topic multitarget drug discovery
MTDLs
tacrine
donepezil
AChE inhibitors
BACE-1 inhibitors
url https://www.mdpi.com/1420-3049/25/15/3337
work_keys_str_mv AT agnieszkazagorska perspectivesfornewandmoreefficientmultifunctionalligandsforalzheimersdiseasetherapy
AT annajaromin perspectivesfornewandmoreefficientmultifunctionalligandsforalzheimersdiseasetherapy
_version_ 1724805163642781696